News & Events zu PRF Technologies Ltd (PRFX)PRFXPRF Technologies Ltd

PRF Technologies Signs Strategic Collaboration with Dotz Nano

PRF Technologies announced that it has signed a non-binding term sheet with Dotz Nano for a strategic collaboration aimed at expanding Dotz's presence in the AI-driven energy optimization market. Dotz would commercialize and ultimately acquire PRF's DeepSolar/GridFeed AI energy platform for $1.0M, and the parties are working toward definitive agreements. Dotz would launch GridFeed in the market under an exclusive license from PRF, and PRF would take an equity position in Dotz through a $250,000 participation in Dotz's recently announced 2.0M Australian dollar placement. Ownership of the platform and its intellectual property would transfer to Dotz once $650,000 of the purchase price has been paid. Completion of the transaction is subject to due diligence, approval by the boards of directors of both companies, and the execution of definitive agreements. With preliminary, unaudited cash, including short-term deposits, of about $11.0M as of September 30, PRF is focused on its healthcare programs. "Our team has developed GridFeed into a validated AI energy platform, and this agreement marks the next stage of its growth. Dotz brings the energy focus and commercialization capabilities to take GridFeed to market, along with a complementary business that optimizes energy use in commercial buildings. The agreement would provide PRF with US$1.0 million and an equity position in Dotz, giving our shareholders continued participation in GridFeed's success, while allowing us to direct our own resources to LayerBio and the Phase 2 trial of OcuRing-K, and to expanding our portfolio of healthcare innovations," said Efraim Cohen-Arazi, interim CEO of PRF Technologies.

PRF Technologies Expands Results for PRF-110 Study

PRF Technologies announced expanded results from its previously reported preclinical study directly comparing its lead product candidate, PRF-110, to Zynrelef, an approved extended-release product used as a benchmark in the study. The expanded results characterize the pharmacokinetic and tissue-distribution properties of PRF-110 alongside the analgesic efficacy data previously announced. PRF-110 is a proprietary, oil-based, viscous, clear extended-release formulation of ropivacaine designed to be deposited directly into the surgical wound bed prior to closure. The product candidate is being developed to provide prolonged local analgesia following surgery through a single administration at the surgical site, with the goal of reducing the use of opioids for post-surgical pain. The study was conducted in a validated porcine post-operative pain model, using von Frey methodology, to assess both analgesic efficacy and PK properties of the two extended-release formulations. PRF-110 and Zynrelef demonstrated similar reductions in mechanical sensitivity, as measured by the von Frey test, indicating comparable pain-relief performance. PRF-110 exhibited a slower absorption rate relative to Zynrelef, suggesting a more gradual release of ropivacaine at the site of administration. PRF-110 showed increased retention in local tissue along with higher local tissue exposure, supporting prolonged availability of the active compound at the target site. Both formulations demonstrated sustained systemic and local drug levels, reinforcing their potential as long-acting analgesic solutions. PRF plans to continue advancing PRF-110 through additional studies to further validate its safety, efficacy and clinical utility across broader surgical settings.

PRF Technologies Files to Sell 7.5M Ordinary Shares

PRF Technologies files to sell 7.5M ordinary shares for holders